Dechra Pharmaceuticals saw the highest growth of 1.99% in patent filings in June and 1.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Dechra Pharmaceuticals‘s patent filings and grants. Buy the databook here.
Dechra Pharmaceuticals has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 67% filings and 25% grants. The European Patent Office(EPO), Australia(AU), United States(US), and Canada(CA) patent Office are among the top ten patent offices where Dechra Pharmaceuticals is filings its patents. Among the top granted patent authorities, Dechra Pharmaceuticals has 50% of its grants in United States(US), 25% in European Patent Office(EPO) and 25% in Canada(CA).
AbbVie and Kenvue could be the strongest competitors for Dechra Pharmaceuticals
Patents related to addiction and climate change lead Dechra Pharmaceuticals's portfolio
Dechra Pharmaceuticals has the highest number of patents in addiction followed by, climate change. For addiction, nearly 100% of patents were filed and 50% of patents were granted in Q2 2024.
Pain related patents lead Dechra Pharmaceuticals portfolio followed by inflammation, and bacterial infections
Dechra Pharmaceuticals has highest number of patents in pain followed by inflammation, bacterial infections, ear infections, and otitis externa. For pain, nearly 50% of patents were filed and 14% of patents were granted in Q2 2024.
For comprehensive analysis of Dechra Pharmaceuticals's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.